DelveInsight’s “Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Kidney Disease, historical and forecasted epidemiology as well as the Diabetic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Diabetic Kidney Disease, offering comprehensive insights into the Diabetic Kidney Disease revenue trends, prevalence, and treatment landscape. The report delves into key Diabetic Kidney Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Diabetic Kidney Disease therapies. Additionally, we cover the landscape of Diabetic Kidney Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Diabetic Kidney Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Diabetic Kidney Disease space.
To Know in detail about the Diabetic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Kidney Disease Market Forecast
Some of the key facts of the Diabetic Kidney Disease Market Report:
-
The Diabetic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
Key Diabetic Kidney Disease Companies: Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Novartis, PhytoHealth Corporation, Eli Lilly and Company, BioStratum, Dong Wha Pharmaceutical, and others.
-
Key Diabetic Kidney Disease Therapies: CU01-1001, BI 685509, BAY94-8862, PF-00489791, telmisartan, Canagliflozin, MT-3995, Nidufexor, PH3, LY3016859, Pyridorin (pyridoxamine dihydrochloride), DW1029M, and others
-
The Diabetic Kidney Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Kidney Disease pipeline products will significantly revolutionize the Diabetic Kidney Disease market dynamics.
-
In February 2023, the European Commission (EC) granted approvalfora label extension for KERENDIA in the European Union (EU) to includeresults on cardiovascular (CV) outcomes from the Phase III FIGARO-DKDstudy.
-
In September 2023, Boehringer Ingelheim and Eli Lilly announced thatthe US FDA approved JARDIANCE 10 mg tablets to reduce the risk ofsustained decline in estimated glomerular filtration rate (eGFR), endstage kidney disease, cardiovascular death, and hospitalization in adults with CKD at risk of progression.
-
In August 2023, Novo Nordisk and Inversago Pharma announced that Novo Nordisk agreed to acquire Inversagofor up to USD 1.075 billionin cash if certain development and commercial milestones areachieved. The acquisition of Inversago includes the company’s leaddevelopment asset INV-202, an oral CB1 inverse agonist.
-
According to DelveInsight estimates, there were approximately 82,858,700 prevalent cases of diabetes across the 7MM in 2023. This number is expected to rise throughout the study period.
-
In 2023, the United States reported the highest number of diagnosed prevalent cases of diabetic kidney disease (DKD), totaling around 5,141,000 cases.
-
It has been noted that diabetic kidney disease (DKD) predominantly affects individuals aged 60 and older, accounting for 70% of cases. In the US, in 2023, there were approximately 1,542,000 cases of DKD among those aged 18–59 years and around 3,600,000 cases in those aged 60 and above.
-
Among the EU4 countries, Germany had the highest number of diabetic kidney disease (DKD) cases in 2023, while France had the lowest number.
Diabetic Kidney Disease Overview
Diabetic Kidney Disease (DKD) is a complication of diabetes characterized by damage to the kidneys’ filtering units due to prolonged high blood sugar levels. It often results in decreased kidney function, which can lead to chronic kidney disease (CKD) or kidney failure if not managed effectively. DKD is marked by proteinuria (excess protein in the urine), hypertension, and declining glomerular filtration rate (GFR). Early detection and management of blood sugar and blood pressure levels are crucial to slowing disease progression and preventing serious outcomes such as end-stage renal disease (ESRD).
Get a Free sample for the Diabetic Kidney Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-market
Diabetic Kidney Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Diabetic Kidney Disease Epidemiology Segmentation:
The Diabetic Kidney Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalent Cases of Diabetes in the 7MM
-
Total Prevalent Cases of DKD in the 7MM
-
Diagnosed Prevalent Cases of DKD in the 7MM
-
Age-specific Cases of DKD in the 7MM
-
Stage-specific Cases of DKD in the 7MM
Download the report to understand which factors are driving Diabetic Kidney Disease epidemiology trends @ Diabetic Kidney Disease Epidemiology Forecast
Diabetic Kidney Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Kidney Disease market or expected to get launched during the study period. The analysis covers Diabetic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diabetic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Diabetic Kidney Disease Therapies and Key Companies
-
CU01-1001: Curacle Co., Ltd.
-
BI 685509: Boehringer Ingelheim
-
BAY94-8862: Bayer
-
PF-00489791: Pfizer
-
telmisartan: Boehringer Ingelheim
-
Canagliflozin: Mitsubishi Tanabe Pharma
-
MT-3995: Mitsubishi Tanabe Pharma
-
Nidufexor: Novartis
-
PH3: Phyto Health Corporation
-
LY3016859: Eli Lilly and Company
-
Pyridorin (pyridoxamine dihydrochloride): BioStratum
-
DW1029M: Dong Wha Pharmaceutical
Discover more about therapies set to grab major Diabetic Kidney Disease market share @ Diabetic Kidney Disease Treatment Landscape
Diabetic Kidney Disease Market Strength
-
Many major companies are investing in different mechanisms of action for the treatment of DKD, peripherally-acting CB1r blockers, IL-33-neutralizing mAb, ETA receptor antagonists, aldosterone synthase inhibitor (ASi), mineralocorticoid receptor (MR) blockers, and others which will boost the DKD market in the future.
-
A unique trial testing of BI 690517, a selective aldosterone synthase inhibitor along with SGLT2 inhibition, showed positive efficacy, offering the potential for additive kidney benefits while possibly mitigating hyperkalemia risk.
Diabetic Kidney Disease Market Opportunities
-
Personalized medicine, considering the genetic and mechanistic variability, will improve renal and cardiovascular protection in diabetic patients with CKD.
-
The concept of “metabolic memory” in diabetic patients, where prior exposure to elevated blood glucose levels results in enduring detrimental effects despite glycemic control, opens a window of opportunity to develop genetic interventions such as CRISPR–Cas editing to potentially erase this memory and offer novel therapeutic avenues for diabetic kidney disease.
Scope of the Diabetic Kidney Disease Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Diabetic Kidney Disease Companies: Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Novartis, PhytoHealth Corporation, Eli Lilly and Company, BioStratum, Dong Wha Pharmaceutical, and others
-
Key Diabetic Kidney Disease Therapies: CU01-1001, BI 685509, BAY94-8862, PF-00489791, telmisartan, Canagliflozin, MT-3995, Nidufexor, PH3, LY3016859, Pyridorin (pyridoxamine dihydrochloride), DW1029M, and others
-
Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
-
Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Diabetic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Diabetic Kidney Disease Market Access and Reimbursement
To know more about Diabetic Kidney Disease companies working in the treatment market, visit @ Diabetic Kidney Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Diabetic Kidney Disease Market Report Introduction
2. Executive Summary for Diabetic Kidney Disease
3. SWOT analysis of Diabetic Kidney Disease
4. Diabetic Kidney Disease Patient Share (%) Overview at a Glance
5. Diabetic Kidney Disease Market Overview at a Glance
6. Diabetic Kidney Disease Disease Background and Overview
7. Diabetic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Diabetic Kidney Disease
9. Diabetic Kidney Disease Current Treatment and Medical Practices
10. Diabetic Kidney Disease Unmet Needs
11. Diabetic Kidney Disease Emerging Therapies
12. Diabetic Kidney Disease Market Outlook
13. Country-Wise Diabetic Kidney Disease Market Analysis (2020–2034)
14. Diabetic Kidney Disease Market Access and Reimbursement of Therapies
15. Diabetic Kidney Disease Market Drivers
16. Diabetic Kidney Disease Market Barriers
17. Diabetic Kidney Disease Appendix
18. Diabetic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:27 Drydock Ave
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services